Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-05-15

FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)

View source ↗

Summary

FDA notice of a supplemental application for INREBIC (fedratinib hydrochloride) submitted by Celgene Corporation; the submission status is AP (supplemental appl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INREBIC (fedratinib hydrochloride)

Snippet

SUPPL AP for INREBIC (FEDRATINIB HYDROCHLORIDE)